Canadian Sec - Free Realtime Quote CAD

AwaknLifeSc (AWKN.CN)

0.0950

0.0000

(0.00%)

As of December 13 at 3:11:37 PM EST. Market Open.

Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD

Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, is pleased to provide an update on its research and development (R&D) programs.Awakn currently has three main R&D programs:1. AWKN-001An investigational, novel combination therapy, consisting of an N-methyl-D-aspartate receptor-

Newsfile 4 days ago

AWKNF
0.00%
Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder

Toronto, Ontario--(Newsfile Corp. - January 20, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA), which took place on December 16, 2024. The meeting addressed the continued development of AWKN-002, a pr

Newsfile 10 days ago

AWKNF
0.00%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Ascend Wellness secured $15 million to boost growth Leafly Holdings transitioned to OTC trading after Nasdaq delisting High Tide expanded into Germany with strategic acquisition Key Takeaways; Psychedelic Sector MindMed provided investor update with detailed plans for 2025 and beyond Awakn secured unsecured credit facility to support research and development Below […]

Market Exclusive 11 days ago

LFLY

LFLYW

MNMD
Awakn Life Sciences Announces Credit Facility

Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that it has obtained an unsecured credit facility of up to US$535,000 (the "Facility") from an arm's length creditor of the Company, which can be drawn upon by the Company in multiple advances, and which ...

Newsfile last month

AWKNF
0.00%
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc

Toronto, Ontario--(Newsfile Corp. - December 16, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that it has entered into a binding letter of intent (the "LOI") dated December 15, 2024, with Graft Polymer (UK) PLC ("Graft"), pursuant to which Graft would acquire all of the issued and outstanding common shares ...

Newsfile last month

AWKNF
0.00%
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program

Toronto, Ontario--(Newsfile Corp. - December 10, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, today announces initial results from a preclinical study of its co-lead aminoindane series (AW21003) conducted by the University of Nottingham. This program focuses on new therapeutic options for trauma-related mental health disorders, parti

Newsfile last month

AWKNF
0.00%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024

Key Takeaways; Cannabis Sector Chicago Atlantic REIT secured a $50 million loan to fund new marijuana investments Canopy Growth reduced loan term by $100 million to strengthen financial position RIV Capital reported doubling revenue, and strong synergy gains ahead of Cansortium merger Key Takeaways; Psychedelic Sector Awakn expanded phase 3 trial sites for alcohol use […]

Market Exclusive 3 months ago

REFI

CNPOF

AWKNF
0.00%
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites

Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces the opening of four additional clinical trial sites: University Hospitals Sussex NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; Greater Manchester Mental Health NHS Foundation Trust; and University Hospitals P

Newsfile 3 months ago

AWKNF
0.00%
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a new research partnership with the University of Nottingham, UK. This collaboration focuses on evaluating Awakn's co-lead aminoindane series and its potential to enhance social cognition and pro-social behaviors.The study will be l

Newsfile 3 months ago

AWKNF
0.00%
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program

Toronto, Ontario--(Newsfile Corp. - October 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), today announced the selection of Eurofins Discovery to conduct initial pharmacology testing for its co-lead aminoindane series as part of Awakn's New Chemical Entity (NCE) pre-

Newsfile 3 months ago

AWKNF
0.00%
Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing

Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, June 4, 2024 and July 31, 2024, it has determined to increase the ...

Newsfile 4 months ago

AWKNF
0.00%
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program

Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to provide an update on the progress of its pre-clinical program being executed as part of a commercial collaboration with Graft Polymer (UK) Plc (LSE: GPL) ("Graft Polymer"), an innovative healthcare industry services company.The collaboration focuses on developing a n

Newsfile 5 months ago

AWKNF
0.00%
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder

Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), announces that the first patient has been screened in the landmark 'MORE-KARE' Phase 3 trial of AWKN-001 for severe AUD. AWKN-001 is an investigational, novel medication-assisted treatment

Newsfile 5 months ago

AWKNF
0.00%
Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension

Toronto, Ontario--(Newsfile Corp. - July 31, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, and June 4, 2024 it has closed a third tranche of its previously ...

Newsfile 5 months ago

AWKNF
0.00%
Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Toronto, Ontario--(Newsfile Corp. - July 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to provide details of the status of the intellectual property ("IP") portfolio for its aminoindane new chemical entity ("NCE") series program (the "Aminoindane NCEs") being devel

Newsfile 6 months ago

AWKNF
0.00%
Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC

Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that it has entered into a commercial collaboration agreement dated July 17, 2024 (the "Collaboration Agreement") with Graft Polymer (UK) Plc (LON: GPL) ("Graft"), an

Newsfile 6 months ago

AWKNF
0.00%
Awakn Life Sciences Announces Closing of Tranche of Private Placement

Toronto, Ontario--(Newsfile Corp. - June 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder, is pleased to announce that, further to its press releases dated April 3, 2024, and April 17, 2024, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (

Newsfile 7 months ago

AWKNF
0.00%
Awakn Life Sciences Discusses Filing of Financial Statements

Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that, it intends to file its audited annual financial statements and MD&A for the financial year ended January 31, 2024 (the "Financial Statements") by May 30, 2024, in line with the standard timeli

Newsfile 8 months ago

AWKNF
0.00%
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic

Awakn also announces Private Placement Toronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the launch of an additional Licensing Partnership agreement in North America. The agreement is with Rivus Wellness and Research Institute ("Rivus"), bas

Newsfile 9 months ago

AWKNF
0.00%
Canadian Securities Exchange Reports February 2024 Performance Figures

Toronto, Ontario--(Newsfile Corp. - March 15, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for February 2024.February 2024 Operating StatisticsTrading volume of CSE listed securities totaled 1.0 billion shares;Trading value of CSE listed securities was $404 million;CSE issuers completed 66 financings that raised an aggregate $66 million; andThe CSE welcomed listings from three new companies, bringing total listed securities to 812 as at Feb

Newsfile 10 months ago

BGX.CN

AWKNF
0.00%
PNXPF

Performance Overview

Return	AWKN.CN	S&P/TSX Composite index
YTD	0.00%	+3.82%
1-Year	-26.92%	+20.41%
3-Year	-95.25%	+23.23%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AwaknLifeSc (AWKN.CN)

Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD

Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Awakn Life Sciences Announces Credit Facility

Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc

Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024

Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites

Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program

Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing

Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program

Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder

Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension

Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC

Awakn Life Sciences Announces Closing of Tranche of Private Placement

Awakn Life Sciences Discusses Filing of Financial Statements

Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic

Canadian Securities Exchange Reports February 2024 Performance Figures

Performance Overview